These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21931969)

  • 1. Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies.
    Gore L; Rivera E; Basche M; Moulder-Thompson SL; Li J; Eppers S; Grolnic S; O'Bryant C; Cleere D; Elsayed YA; Eckhardt SG
    Invest New Drugs; 2012 Oct; 30(5):1942-9. PubMed ID: 21931969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies.
    von Mehren M; Bookman M; Meropol NJ; Weiner LM; Sherman E; Li J; Knoblauch R; Parekh T; Cohen RB
    Cancer Chemother Pharmacol; 2015 May; 75(5):1047-55. PubMed ID: 25791363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
    Chu Q; Mita A; Forouzesh B; Tolcher AW; Schwartz G; Nieto A; Soto-Matos A; Alfaro V; Lebedinsky C; Rowinsky EK
    Clin Cancer Res; 2010 May; 16(9):2656-65. PubMed ID: 20406837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.
    Messersmith WA; Jimeno A; Ettinger D; Laheru D; Brahmer J; Lansey D; Khan Y; Donehower RC; Elsayed Y; Zannikos P; Hidalgo M
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):181-8. PubMed ID: 18379785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors.
    Sessa C; Del Conte G; Christinat A; Cresta S; Perotti A; Gallerani E; Lardelli P; Kahatt C; Alfaro V; Iglesias JL; Fernández-Teruel C; Gianni L
    Invest New Drugs; 2013 Oct; 31(5):1236-43. PubMed ID: 23467812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
    Sweeney CJ; Chiorean EG; Verschraegen CF; Lee FC; Jones S; Royce M; Tye L; Liau KF; Bello A; Chao R; Burris HA
    J Clin Oncol; 2010 Oct; 28(29):4513-20. PubMed ID: 20837944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
    Saif MW; Lansigan F; Ruta S; Lamb L; Mezes M; Elligers K; Grant N; Jiang ZL; Liu SH; Cheng YC
    Phytomedicine; 2010 Mar; 17(3-4):161-9. PubMed ID: 20092990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
    Deenen MJ; Klümpen HJ; Richel DJ; Sparidans RW; Weterman MJ; Beijnen JH; Schellens JH; Wilmink JW
    Invest New Drugs; 2012 Aug; 30(4):1557-65. PubMed ID: 21809026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
    Forouzesh B; Hidalgo M; Chu Q; Mita A; Mita M; Schwartz G; Jimeno J; Gómez J; Alfaro V; Lebedinsky C; Zintl P; Rowinsky EK
    Clin Cancer Res; 2009 May; 15(10):3591-9. PubMed ID: 19417019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.
    Chu QS; Schwartz G; de Bono J; Smith DA; Koch KM; Versola MJ; Pandite L; Arya N; Curtright J; Fleming RA; Ho PT; Rowinsky EK
    J Clin Oncol; 2007 Aug; 25(24):3753-8. PubMed ID: 17704424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.
    von Mehren M; Schilder RJ; Cheng JD; Temmer E; Cardoso TM; Renshaw FG; Bayever E; Zannikos P; Yuan Z; Cohen RB
    Ann Oncol; 2008 Oct; 19(10):1802-9. PubMed ID: 18497430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
    Sayar H; Shen Z; Lee SJ; Royce M; Rabinowitz I; Lee F; Smith H; Eberhardt S; Maestas A; Lu H; Verschraegen C
    Invest New Drugs; 2009 Apr; 27(2):153-8. PubMed ID: 18773144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
    Mazard T; Ychou M; Thezenas S; Poujol S; Pinguet F; Thirion A; Bleuse JP; Portales F; Samalin E; Assenat E
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):807-14. PubMed ID: 22037922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
    Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors.
    Vidal L; Magem M; Barlow C; Pardo B; Florez A; Montes A; Garcia M; Judson I; Lebedinsky C; Kaye SB; Salazar R
    Invest New Drugs; 2012 Apr; 30(2):616-28. PubMed ID: 20927639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.
    Alexandre J; Kahatt C; Bertheault-Cvitkovic F; Faivre S; Shibata S; Hilgers W; Goldwasser F; Lokiec F; Raymond E; Weems G; Shah A; MacDonald JR; Cvitkovic E
    Invest New Drugs; 2007 Oct; 25(5):453-62. PubMed ID: 17628744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
    Shin SJ; Ahn JB; Park KS; Lee YJ; Hong YS; Kim TW; Kim HR; Rha SY; Roh JK; Kim DH; Kim C; Chung HC
    Invest New Drugs; 2012 Apr; 30(2):672-80. PubMed ID: 21188464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.
    Gore L; Holden SN; Cohen RB; Morrow M; Pierson AS; O'Bryant CL; Persky M; Gustafson D; Mikule C; Zhang S; Palmer PA; Eckhardt SG
    Ann Oncol; 2006 Nov; 17(11):1709-17. PubMed ID: 16980604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.
    Sessa C; Cresta S; Noberasco C; Capri G; Gallerani E; De Braud F; Zucchetti M; D'Incalci M; Locatelli A; Marsoni S; Corradino I; Minoia C; Zintl P; Gianni L
    Eur J Cancer; 2009 Aug; 45(12):2116-22. PubMed ID: 19419856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.